Justin Hales, CEO and founder of Camplify, joins Chris Titley to discuss the company’s evolution from an RV rental marketplace into a broader RV lifecycle business operating across seven countries.

The conversation covers Camplify’s expansion into insurance, managed services and classifieds, its focus on profit led growth and the role of AI across the business. Justin also discusses the company’s relationship with JB Group as a strategic partner and shareholder, changing customer demand and Camplify’s priorities as it works towards its 2030 vision.

----

This content is factual information only, does not contain financial product advice and has not been prepared in consideration of your personal circumstances or needs. Views shared by individuals are their own personal views and not the views of Scoreboard Media. We are not licensed to provide financial product advice and cannot make investment recommendations to you. Investments carry risk. Please consider seeking professional financial advice, and read the relevant disclosure documents, before making any decisions to invest in financial products.

Pointerra and Scoreboard Media are in a commercial arrangement which includes payment for time spent researching, producing, and editing video and podcast content. All questioning is created by Scoreboard Media, not CHL.

In this episode, Chris Titley sits down with Ian Olson, Co-founder and CEO of ASX-listed Pointerra, for a detailed investor deep dive into one of the more under-the-radar infrastructure SaaS stories.

Pointerra sits at the intersection of geospatial data, digital twins, and enterprise software—helping organisations manage massive, complex physical assets across utilities, mining, transport, and energy.

Ian breaks down how the business has evolved from solving data management problems into becoming a critical platform for interpreting and acting on infrastructure data at scale. The conversation explores how digital twins are being adopted across industries, why enterprise customers are increasingly relying on cloud-based workflows, and how Pointerra is positioning itself within that shift.

They also cover:

• The transition from project-based revenue to recurring SaaS models
• Entering and scaling in the US market
• How AI is impacting both product development and go-to-market strategy
• Why customer-led development has shaped the platform
• The long-term opportunity across utilities, mining, and infrastructure

A practical, in-depth discussion on what it actually takes to build and scale a B2B SaaS company in complex, asset-heavy industries.

Disclaimer

This content is factual information only, does not contain financial product advice and has not been prepared in consideration of your personal circumstances or needs. Views shared by individuals are their own personal views and not the views of Sub11. We are not licenced to provide financial product advice and cannot make investment recommendations to you. Investments carry risk. Please consider seeking professional financial advice, and read the relevant disclosure documents, before making any decisions to invest in financial products.

Pointerra and Sub11 are in a commercial arrangement which includes time spent researching, producing, and editing video and podcast content. All questioning is created by Sub11, not Pointerra.

🎙️ Sub11: Control Bionics — EMG, Impact & Innovation

In this episode of Sub11, Chris Titley sits down with Jeremy Steele, CEO of ASX-listed medtech company Control Bionics.

Jeremy unpacks how a pioneering Australian technology—originally used by Stephen Hawking—is now changing lives across assistive communication, rehabilitation, and sports performance. From enabling non-verbal individuals to communicate, to boosting vertical jump height in elite athletes, Control Bionics is using surface electromyography (EMG) to interpret human intent like never before.

We discuss:

• How the NeuroNode and NeuroStrip work
• Partnerships and global expansion
• Their recent investment in NeuroBounce
• AI’s role in personalised performance and injury prevention
• Commercial traction, regulatory wins, and blue-sky potential

Plus, Jeremy shares a moving story of a young man in Japan who used the technology to speak to his mother for the first time in 20 years.

This is a 101 on a company using Australian-born tech to create global impact.

This content is factual information only, does not contain financial product advice and has not been prepared in consideration of your personal circumstances or needs. Views shared by individuals are their own personal views and not the views of Sub11. We are not licenced to provide financial product advice and cannot make investment recommendations to you. Investments carry risk. Please consider seeking professional financial advice, and read the relevant disclosure documents, before making any decisions to invest in financial products.

Control Bionics and Sub11 are in a commercial relationship which includes the production of media assets for use on LinkedIn. All questioning is created by Sub11, not Control Bionics.

This interview mainly discussed the journey and evolution of Audeara, a hearing health technology company founded by James Fielding.

The conversation covered the company's inception in 2015, its transition from a B2C to a B2B model, and its current position as a global player in the hearing health industry.

James Fielding detailed the company's initial focus on creating headphones with built-in hearing tests, which evolved into personalized audio solutions.

He highlighted key milestones such as their successful Kickstarter campaign in 2017, the challenges of product development and delivery, and securing government contracts and partnerships with major audiology companies worldwide.

The interview also touched on Audeara's shift towards licensing their technology to other brands, their expansion into international markets, particularly Asia, and their recent financial successes. Fielding emphasised the company's commitment to improving hearing health awareness and accessibility, discussing partnerships with companies like Zildjian and their entry into the Chinese medical device market.

The conversation concluded with insights into Audeara's future growth strategies, the balance between growth and capital efficiency, and the company's progress towards profitability.

This content is factual information only, does not contain financial product advice and has not been prepared in consideration of your personal circumstances or needs. Views shared by individuals are their own personal views and not the views of Sub11. We are not licenced to provide financial product advice and cannot make investment recommendations to you. Investments carry risk. Please consider seeking professional financial advice, and read the relevant disclosure documents, before making any decisions to invest in financial products.

Audeara and Sub11 are in a commercial relationship which includes production of media mediums such as video, audio and social media. All questioning is created by Sub11, not Audeara.

The podcast is an interview with James Durrant, the Managing Director of RareX, an ASX-listed company focused on rare earth elements (REEs) and phosphate mining.

James discusses his background as a mining engineer and his experience working for companies like BHP Billiton before joining RareX.

He explains the importance of REEs in modern technology, particularly in electric vehicles, wind turbines, and defense systems.

RareX's main project is the Cummins Range project in Australia, which contains significant deposits of REEs and phosphate.

The company plans to develop the phosphate aspect first as a low-cost entry point before moving into REE production.

James also mentions RareX's recent acquisition of the Khaleesi project, which is prospective for REEs, niobium, base metals, and precious metals.

The company is exploring opportunities for expansion, particularly in Saudi Arabia and Eastern Africa, to leverage its expertise and become a near-term developer of REE projects.

Key catalysts for investors in the next 12 months include drilling at the Khaleesi project, progress on the Cummins Range project's engineering and approvals, and potential strategic deals for project expansion.

This content is factual information only, does not contain financial product advice and has not been prepared in consideration of your personal circumstances or needs. Views shared by individuals are their own personal views and not the views of Sub11. We are not licenced to provide financial product advice and cannot make investment recommendations to you. Investments carry risk. Please consider seeking professional financial advice, and read the relevant disclosure documents, before making any decisions to invest in financial products.

The article is a transcript of a podcast interview with Dr. Mike Jones, the Managing Director of Impact Minerals.

Mike discusses the history of the company, which was founded in 2006 with the goal of finding a world-class ore body.

He talks about the company's focus on commodities like gold, copper, nickel, and more recently, high-purity alumina (HPA).

The main project discussed is the Lake Hope HPA project, which Mike believes has the potential to produce HPA at extremely low costs due to its unique geology.

He provides details on the project's ownership structure, recent milestones, and future plans, including completing a pre-feasibility study by the end of 2023, followed by a definitive feasibility study and potential final investment decision in 2026.

Mike also discusses the company's other projects, including potential spin-offs and joint ventures, and touches on the potential impact of technological advancements, such as material science, on the mining industry.

This content is factual information only, does not contain financial product advice and has not been prepared in consideration of your personal circumstances or needs. Views shared by individuals are their own personal views and not the views of Sub11. We are not licenced to provide financial product advice and cannot make investment recommendations to you. Investments carry risk. Please consider seeking professional financial advice, and read the relevant disclosure documents, before making any decisions to invest in financial products.

This content is factual information only, does not contain financial product advice and has not been prepared in consideration of your personal circumstances or needs. Views shared by individuals are their own personal views and not the views of Sub11. We are not licenced to provide financial product advice and cannot make investment recommendations to you. Investments carry risk. Please consider seeking professional financial advice, and read the relevant disclosure documents, before making any decisions to invest in financial products.

This Podcast is an interview with Michael Baker, CEO and Managing Director of Arovella Therapeutics , a biotechnology company focused on developing cell therapies for cancer treatment. Michael discusses his background, transitioning from a research scientist to venture capital and then joining Arovella in 2020. He explains Arovella's work on CAR-iNKT cell therapies, which involve genetically reprogramming a patient's immune cells to target and kill cancer cells.

Michael highlights the advantages of Arovella's approach over traditional CAR-T cell therapies, including faster manufacturing, lower costs, and the ability to treat multiple patients from a single manufacturing run.

He outlines recent milestones, such as completing the manufacturing process development and scaling up for clinical trials. Michael also discusses the competitive landscape, potential partnerships and acquisitions in the cell therapy sector, target markets, and upcoming milestones for Aravella, including regulatory submissions, animal studies, and exploring new technologies.

This content is factual information only, does not contain financial product advice and has not been prepared in consideration of your personal circumstances or needs. Views shared by individuals are their own personal views and not the views of Sub11. We are not licenced to provide financial product advice and cannot make investment recommendations to you. Investments carry risk. Please consider seeking professional financial advice, and read the relevant disclosure documents, before making any decisions to invest in financial products.